CN102781958B - 基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗 - Google Patents

基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗 Download PDF

Info

Publication number
CN102781958B
CN102781958B CN201080063115.5A CN201080063115A CN102781958B CN 102781958 B CN102781958 B CN 102781958B CN 201080063115 A CN201080063115 A CN 201080063115A CN 102781958 B CN102781958 B CN 102781958B
Authority
CN
China
Prior art keywords
ferlin
epitope
composition
protein
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201080063115.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN102781958A (zh
Inventor
A-K.米勒
E.莫拉特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet Heidelberg
Original Assignee
Malwa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Malwa Co Ltd filed Critical Malwa Co Ltd
Publication of CN102781958A publication Critical patent/CN102781958A/zh
Application granted granted Critical
Publication of CN102781958B publication Critical patent/CN102781958B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201080063115.5A 2009-12-05 2010-12-06 基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗 Expired - Fee Related CN102781958B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US26702609P 2009-12-05 2009-12-05
US61/267026 2009-12-05
PCT/EP2010/007399 WO2011066995A1 (en) 2009-12-05 2010-12-06 Malaria vaccines based on apicomplexan ferlins, ferlin-like proteins and other c2-domain containing proteins

Publications (2)

Publication Number Publication Date
CN102781958A CN102781958A (zh) 2012-11-14
CN102781958B true CN102781958B (zh) 2017-07-11

Family

ID=43499977

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080063115.5A Expired - Fee Related CN102781958B (zh) 2009-12-05 2010-12-06 基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗

Country Status (8)

Country Link
US (1) US8968750B2 (https=)
EP (1) EP2507259B1 (https=)
JP (1) JP2013512866A (https=)
CN (1) CN102781958B (https=)
BR (1) BR112012013581A8 (https=)
CA (1) CA2783107C (https=)
MX (1) MX2012006458A (https=)
WO (1) WO2011066995A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103491979B (zh) 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗
AU2014203873A1 (en) * 2013-01-07 2015-07-30 Biomedical Research Models, Inc. Therapeutic vaccines for treating herpes simplex virus type 2 infections
AU2015305754B2 (en) 2014-08-19 2018-10-25 Merck Sharp & Dohme Llc Anti-tigit antibodies
EP3334757A4 (en) * 2015-08-14 2019-04-03 Merck Sharp & Dohme Corp. ANTI-Tigit ANTIBODY
JP2017210441A (ja) * 2016-05-26 2017-11-30 国立大学法人大阪大学 マラリアワクチン

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244126A (zh) * 1997-01-21 2000-02-09 纽约大学 用于抗疟疾疫苗的通用t细胞表位

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4518528A (en) * 1983-05-19 1985-05-21 Rasnick David W α Amino fluoro ketones
US5198334A (en) * 1989-07-21 1993-03-30 Terumo Corporation Protection of natural killer cell cytolytic activity in peripheral blood mononuclear cells
GB9406492D0 (en) * 1994-03-31 1994-05-25 Isis Innovation Malaria peptides
US20030077653A1 (en) * 2000-04-20 2003-04-24 The University Of Georgia Research Foundation, Inc. Method for the identification of active site protease inactivators
US7811575B2 (en) * 2001-04-10 2010-10-12 Agensys, Inc. Nucleic acids and corresponding proteins entitled 158P3D2 useful in treatment and detection of cancer
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
CA2409897A1 (en) 2002-10-25 2004-04-25 Institut Pasteur Plasmodium falciparum virulence factor var o
US7198791B2 (en) 2003-03-03 2007-04-03 Pluschke, Gerd Et Al. Compositions and methods for the generation of protective immune responses against malaria
US8206725B2 (en) * 2003-08-26 2012-06-26 The Council Of The Queensland Institute Of Medical Research Immunogenic agent and pharmaceutical composition for use against homologous and heterologous pathogens including plasmodium SPP
WO2005063804A1 (en) 2003-12-30 2005-07-14 Københavns Universitet Panum Compounds useful in the diagnosis and treatment of malaria
US7951782B2 (en) * 2005-09-29 2011-05-31 Maruha Nichiro Seafoods, Inc Composition effective to prevent or treat adult disease
GB0601059D0 (en) * 2006-01-19 2006-03-01 Univ Durham Target
WO2009082440A2 (en) 2007-12-18 2009-07-02 Vaxinnate Corporation Compositions of toll-like receptor agonists and malaria antigens and methods of use
US8343498B2 (en) * 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8277812B2 (en) * 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) * 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US20110165649A1 (en) * 2010-01-06 2011-07-07 Brett Tyler Methods and compositions to improve the health of plants, animals and microbes by manipulating protein entry into symbionts and their hosts
CN103491979B (zh) * 2010-12-06 2016-12-21 马尔瓦有限责任公司 基于来自恶性疟原虫的红细胞前期抗原的疟疾疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1244126A (zh) * 1997-01-21 2000-02-09 纽约大学 用于抗疟疾疫苗的通用t细胞表位

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
XP_001348704.1;NCBI;《NCBI Reference Sequence》;www.ncbi.nlm.nih.gov;20090916;序列 *

Also Published As

Publication number Publication date
US20120308598A1 (en) 2012-12-06
JP2013512866A (ja) 2013-04-18
EP2507259B1 (en) 2016-08-24
BR112012013581A8 (pt) 2017-12-26
WO2011066995A1 (en) 2011-06-09
US8968750B2 (en) 2015-03-03
CA2783107C (en) 2018-08-07
EP2507259A1 (en) 2012-10-10
CN102781958A (zh) 2012-11-14
MX2012006458A (es) 2012-09-07
BR112012013581A2 (pt) 2017-01-10
CA2783107A1 (en) 2011-06-09

Similar Documents

Publication Publication Date Title
Aly et al. Targeted deletion of SAP1 abolishes the expression of infectivity factors necessary for successful malaria parasite liver infection
Kemp et al. Subversion of host cellular functions by the apicomplexan parasites
van Dijk et al. A central role for P48/45 in malaria parasite male gamete fertility
Sjölander et al. Induction of a Th1 immune response and simultaneous lack of activation of a Th2 response are required for generation of immunity to leishmaniasis
Wilson et al. Differential regulation of effector-and central-memory responses to Toxoplasma gondii Infection by IL-12 revealed by tracking of Tgd057-specific CD8+ T cells
Grover et al. The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden
Malkin et al. Phase 1 study of two merozoite surface protein 1 (MSP142) vaccines for Plasmodium falciparum malaria
Espinosa et al. Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy
Fox et al. Secretion of rhoptry and dense granule effector proteins by nonreplicating Toxoplasma gondii uracil auxotrophs controls the development of antitumor immunity
CN102781958B (zh) 基于顶复虫Ferlin、Ferlin样蛋白和其它含有C2结构域的蛋白的疟疾疫苗
Gimenez et al. A universal vaccine candidate against Plasmodium vivax malaria confers protective immunity against the three Pv CSP alleles
Nico et al. Cross-protective immunity to Leishmania amazonensis is mediated by CD4+ and CD8+ epitopes of Leishmania donovani nucleoside hydrolase terminal domains
Charest et al. Recombinant attenuated Toxoplasma gondii expressing the Plasmodium yoelii circumsporozoite protein provides highly effective priming for CD8+ T cell-dependent protective immunity against malaria
Radwanska et al. Antibodies raised against the flagellar pocket fraction of Trypanosoma brucei preferentially recognize HSP60 in cDNA expression library
Nico et al. Adaptive immunity against Leishmania nucleoside hydrolase maps its C-terminal domain as the target of the CD4+ T cell–driven protective response
US7115361B2 (en) Detection of CD8+ T cell responses to M. tuberculosis
Cherif et al. Nanoparticle formulation enhanced protective immunity provoked by PYGPI8p-transamidase related protein (PyTAM) DNA vaccine in Plasmodium yoelii malaria model
Sedegah et al. Identification and localization of minimal MHC-restricted CD8+ T cell epitopes within the Plasmodium falciparum AMA1 protein
JP2017527293A (ja) 三成分多段階マラリアワクチン
Mortazavidehkordi et al. Evaluation of a novel lentiviral vaccine expressing KMP 11‐HASPB fusion protein against Leishmania infantum in BALB/c mice
Lee et al. Dimorphic Plasmodium falciparum merozoite surface protein‐1 epitopes turn off memory T cells and interfere with T cell priming
Wang et al. Immune responses to Plasmodium vivax pre‐erythrocytic stage antigens in naturally exposed Duffy‐negative humans: a potential model for identification of liver‐stage antigens
US10548960B2 (en) Malaria vaccines based on pre-erythrocytic antigens from P. falciparum
Changrob et al. Naturally-acquired immune response against Plasmodium vivax rhoptry-associated membrane antigen
Hon et al. Conservation of S20 as an Ineffective and Disposable IFNγ-Inducing Determinant of Plasmodium Sporozoites Indicates Diversion of Cellular Immunity

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160108

Address after: Heidelberg

Applicant after: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG

Address before: Heidelberg

Applicant before: RUPRECHT-KARLS-UNIVERSITAT HEIDELBERG

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170711